Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-14 4:52 pm Unchanged | 2026-06-30 | 13G | SAB BIOTHERAPEUTICS INC NE SABS | Caligan Partners LP | 7,967,207 8.800% | 0 (Unchanged) | Filing History |
| 2026-08-14 4:40 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 3,163,866 5.900% | 1,528,843 (+93.51%) | Filing History |
| 2026-08-14 4:32 pm Purchase | 2026-06-30 | 13G | OPUS GENETICS, INC. IRD | Caligan Partners LP | 6,077,084 7.300% | 2,056 (+0.03%) | Filing History |
| 2026-08-14 4:22 pm Purchase | 2026-06-30 | 13G | FAETH THERAPEUTICS INC FTH | Caligan Partners LP | 629,467 2.400% | 503,465 (+399.57%) | Filing History |
| 2026-08-14 4:08 pm Purchase | 2026-06-30 | 13G | CELLECTAR BIOSCIENCES INC CLRB | Caligan Partners LP | 469,998 5.900% | 469,998 (New Position) | Filing History |
| 2026-05-15 11:17 am Purchase | 2026-03-31 | 13G | SAB BIOTHERAPEUTICS INC NE SABS | Caligan Partners LP | 7,967,207 10.400% | 7,967,207 (New Position) | Filing History |
| 2026-05-15 10:56 am Purchase | 2026-03-31 | 13G | OPUS GENETICS, INC. IRD | Caligan Partners LP | 6,075,028 8.500% | 6,075,028 (New Position) | Filing History |
| 2026-05-15 10:43 am Purchase | 2026-03-31 | 13G | LB PHARMACEUTICALS INC LBRX | Caligan Partners LP | 1,438,070 5.000% | 1,438,070 (New Position) | Filing History |
| 2026-05-15 10:31 am Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 1,635,023 7.200% | 753,490 (+85.47%) | Filing History |
| 2026-05-15 08:32 am Purchase | 2026-03-31 | 13G | FAETH THERAPEUTICS INC FTH | Caligan Partners LP | 126,002 9.400% | 126,002 (New Position) | Filing History |
| 2026-02-17 5:00 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 881,533 4.900% | 48,200 (+5.78%) | Filing History |
| 2026-02-17 4:56 pm Sale | 2025-12-31 | 13G | EVOLUS INC EOLS | Caligan Partners LP | 0 0.000% | -4,138,943 (Position Closed) | Filing History |
| 2026-01-27 7:29 pm Unchanged | 2026-01-23 | 13D | ANIKA THERAPEUTICS INC ANIK | Caligan Partners LP | 1,435,130 9.950% | 0 (Unchanged) | Filing History |
| 2025-12-30 07:10 am Unchanged | 2025-12-26 | 13D | VERRICA PHARMACEUTICALS INC CO VRCA | Caligan Partners LP | 6,503,054 9.990% | 0 (Unchanged) | Filing History |
| 2025-11-24 4:15 pm Purchase | 2025-11-23 | 13D | VERRICA PHARMACEUTICALS INC CO VRCA | Caligan Partners LP | 6,503,054 9.990% | 4,917,389 (+310.12%) | Filing History |
| 2025-11-21 09:21 am Sale | 2025-11-19 | 13D | ANIKA THERAPEUTICS INC ANIK | Caligan Partners LP | 1,435,130 9.950% | -863 (-0.06%) | Filing History |
| 2025-11-14 2:34 pm Sale | 2025-09-30 | 13G | Y-MABS THERAPEUTICS INC YMAB | Caligan Partners LP | 0 0.000% | -2,342,609 (Position Closed) | Filing History |
| 2025-11-14 2:31 pm Purchase | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 833,333 6.300% | 833,333 (New Position) | Filing History |
| 2025-11-14 2:30 pm Purchase | 2025-09-30 | 13G | EVOLUS INC EOLS | Caligan Partners LP | 4,138,943 6.400% | 796,973 (+23.85%) | Filing History |
| 2025-08-14 4:15 pm Purchase | 2025-06-30 | 13G | EVOLUS INC EOLS | Caligan Partners LP | 3,341,970 5.200% | 3,341,970 (New Position) | Filing History |